D
Daniel J. Cuthbertson
Researcher at University of Liverpool
Publications - 196
Citations - 7113
Daniel J. Cuthbertson is an academic researcher from University of Liverpool. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 38, co-authored 154 publications receiving 5184 citations. Previous affiliations of Daniel J. Cuthbertson include University of Dundee & National Health Service.
Papers
More filters
Journal ArticleDOI
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
Daniel J. Cuthbertson,Kenneth Smith,Kenneth Smith,John A. Babraj,Graham P. Leese,T Waddell,Philip J. Atherton,Philip J. Atherton,Henning Wackerhage,Peter M. Taylor,M. J. Rennie,M. J. Rennie +11 more
TL;DR: It is demonstrated that EAA stimulate MPS independently of increased insulin availability, and in the elderly, a deficit in MPS in the basal state is unlikely; and the decreased sensitivity and responsiveness of MPS to EAA, associated with decrements in the expression and activation of components of anabolic signaling pathways, are probably major contributors to the failure of muscle maintenance inThe elderly.
Journal ArticleDOI
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy.
Zohaib Iqbal,Shazli Azmi,Rahul Yadav,Maryam Ferdousi,Mohit Kumar,Daniel J. Cuthbertson,Jonathan Lim,Rayaz A. Malik,Uazman Alam,Uazman Alam +9 more
TL;DR: Clinical recognition of DPN is imperative for allowing timely symptom management to reduce the morbidity associated with this condition and consider potential new pharmacotherapies for painful DPN.
Journal ArticleDOI
Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study.
A Dennis,Malgorzata Wamil,Malgorzata Wamil,Johann Alberts,Jude Oben,Daniel J. Cuthbertson,Daniel G. Wootton,Michael Crooks,Mark Gabbay,Michael Brady,Lyth Hishmeh,Emily Attree,Melissa Heightman,Rajarshi Banerjee,Amitava Banerjee +14 more
TL;DR: In this paper, the authors assessed medium-term organ impairment in symptomatic individuals following recovery from acute SARS-CoV-2 infection and age-matched healthy controls, and found that 60% of individuals had 10 or more symptoms and 60% had severe post-COVID-19 syndrome.
Journal ArticleDOI
Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Daniel J. Cuthbertson,Andrew J. Irwin,Chris J Gardner,Christina Daousi,Tej Purewal,Niall Furlong,Niru Goenka,E. Louise Thomas,V.L. Adams,Sudeep Pushpakom,Munir Pirmohamed,Graham J. Kemp +11 more
TL;DR: The impact of 6 months’ GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis was determined and the inter-relationship between changes in IHL with those in glycosylated haemoglobin, body weight, and volume of abdominal visceral and subcutaneous adipose tissue was evaluated.
Journal ArticleDOI
Polycystic Ovary Syndrome with Hyperandrogenism Is Characterized by an Increased Risk of Hepatic Steatosis Compared to Nonhyperandrogenic PCOS Phenotypes and Healthy Controls, Independent of Obesity and Insulin Resistance
Helen Jones,Victoria S. Sprung,Christopher J. A. Pugh,Christina Daousi,Andrew J. Irwin,Nabil Aziz,V.L. Adams,E. Louise Thomas,Jimmy D. Bell,Graham J. Kemp,Daniel J. Cuthbertson +10 more
TL;DR: It is suggested that HA-PCOS is associated with hepatic steatosis, independent of obesity and insulin resistance, in women with polycystic ovary syndrome.